News | August 05, 2021
Dr. Reddy's Laboratories signs asset purchase agreement with BioDelivery Sciences
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Innovative solutions and a deep understanding of the market makes this a unique combination
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
Complementary business models are the reason for the acquisition
The company is confident of commencing production at both Mahad and Chiplun units soon
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Subscribe To Our Newsletter & Stay Updated
